Inventor · disambiguated record
Martin Sendzik
Also filed as: SENDZIK MARTIN
38 granted patents·20 pending applications·331 citations·filing 2001–2024
98Inventor score
Files withNOVARTIS AG26PHARMACYCLICS INC7BARSANTI PAUL A4CAFERRO THOMAS RAYMOND3ANTONIOS-MCCREA WILLIAM R2
Top patents by PatentIndex Score
58 records- 0193US11207325B2Triazolopyrimidine compounds and uses thereofNOVARTIS AG·Filed 2020·Granted Dec 28, 2021·3 cites·19 claims
- 0293US7420089B2Hydroxamates as therapeutic agentsPHARMACYCLICS INC·Filed 2007·Granted Sep 2, 2008·17 cites·10 claims
- 0392US10968235B2N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2NOVARTIS AG·Filed 2019·Granted Apr 6, 2021·3 cites·3 claims
- 0492US10934285B2Compounds and compositions for inhibiting the activity of SHP2NOVARTIS AG·Filed 2017·Granted Mar 2, 2021·5 cites·5 claims
- 0592US10077276B2N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2CHEN CHRISTINE HIU TUNG·Filed 2015·Granted Sep 18, 2018·15 cites·22 claims
- 0692US7276612B2Hydroxamates as therapeutic agentsPHARMACYCLICS INC·Filed 2004·Granted Oct 2, 2007·39 cites·18 claims
- 0791US8779171B2Hydroxamates as therapeutic agentsPHARMACYCLICS INC·Filed 2013·Granted Jul 15, 2014·9 cites·15 claims
- 0891US8202876B2Compounds and compositions as protein kinase inhibitorsALBAUGH PAMELA·Filed 2007·Granted Jun 19, 2012·39 cites·9 claims
- 0990US10336774B2N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2NOVARTIS AG·Filed 2018·Granted Jul 2, 2019·7 cites·22 claims
- 1090US9815813B21-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions therefor for inhibiting the activity of SHP2CHEN ZHUOLIANG·Filed 2015·Granted Nov 14, 2017·13 cites·8 claims
- 1190US8026371B2Hydroxamates as therapeutic agentsPHARMACYCLICS INC·Filed 2010·Granted Sep 27, 2011·9 cites·12 claims
- 1290US7553854B26-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signalingNOVARTIS VACCINES & DIAGNOSTIC·Filed 2007·Granted Jun 30, 2009·20 cites·78 claims
- 1389US9580437B2Triazolopyrimidine compounds and uses thereofCHAN HO MAN·Filed 2015·Granted Feb 28, 2017·15 cites·20 claims
- 1489US8865732B2Heterocyclic compounds and uses thereofHUANG ZILIN·Filed 2012·Granted Oct 21, 2014·12 cites·10 claims
- 1588US10301278B21-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions therefor for inhibiting the activity of SHP2NOVARTIS AG·Filed 2017·Granted May 28, 2019·8 cites·7 claims
- 1688US8389570B2Hydroxamates as therapeutic agentsVERNER ERIK J·Filed 2011·Granted Mar 5, 2013·11 cites·15 claims
- 1786US10287266B2Compounds and compositions for inhibiting the activity of SHP2NOVARTIS AG·Filed 2016·Granted May 14, 2019·8 cites·13 claims
- 1886US8710048B26-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signalingSUTTON JAMES C·Filed 2012·Granted Apr 29, 2014·12 cites·28 claims
- 1985US8957068B23-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDHCAFERRO THOMAS RAYMOND·Filed 2012·Granted Feb 17, 2015·13 cites·28 claims
- 2084US9434719B23-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDHCAFERRO THOMAS RAYMOND·Filed 2014·Granted Sep 6, 2016·7 cites·16 claims
- 2184US8129394B2Heteroaryl-substituted imidazole compounds and uses thereofHUNAG ZILIN·Filed 2009·Granted Mar 6, 2012·17 cites·13 claims
- 2282US10167279B2Compounds and compositions as RAF kinase inhibitorsNOVARTIS AG·Filed 2015·Granted Jan 1, 2019·3 cites·17 claims
- 2381US10689378B2Triazolopyridine compounds and uses thereofNOVARTIS AG·Filed 2017·Granted Jun 23, 2020·4 cites·18 claims
- 2481US10220036B2Triazolopyrimidine compounds and uses thereofNOVARTIS AG·Filed 2015·Granted Mar 5, 2019·3 cites·26 claims
- 2581US8415381B2Heteroaryl compounds and their usesBARSANTI PAUL A·Filed 2010·Granted Apr 9, 2013·7 cites·12 claims
- 2680US9688672B23-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDHNOVARTIS AG·Filed 2016·Granted Jun 27, 2017·2 cites·14 claims
- 2779US10676479B2Imidazolepyridine compounds and uses thereofNOVARTIS AG·Filed 2017·Granted Jun 9, 2020·2 cites·10 claims
- 2879US8778951B2Heteroaryl compounds and their usesNOVARTIS AG·Filed 2013·Granted Jul 15, 2014·4 cites·8 claims
- 2979US6861419B2Substituted 1, 4-thiazepine and analogs as activators of caspases and inducers of apoptosis and the use thereofCYTOVIA INC·Filed 2001·Granted Mar 1, 2005·12 cites·40 claims
- 3079US2024199609A1Compounds and compositions for inhibiting the activity of shp2NOVARTIS AG·Filed 2023·Application pending·0 cites
- 3177US7368572B2Acetylene derivatives as inhibitors of histone deacetylasePHARMACYCLICS INC·Filed 2004·Granted May 6, 2008·8 cites·12 claims
- 3277US2022073537A1N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2NOVARTIS AG·Filed 2021·Application pending·0 cites
- 3376US9186347B1Hydroxamates as therapeutic agentsPHARMACYCLICS LLC·Filed 2015·Granted Nov 17, 2015·1 cites·7 claims
- 3475US11952386B2N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2NOVARTIS AG·Filed 2021·Granted Apr 9, 2024·0 cites·12 claims
- 3575US11931363B2Triazolopyrimidine compounds and uses thereofNOVARTIS AG·Filed 2021·Granted Mar 19, 2024·0 cites·22 claims
- 3674US12209098B2N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2NOVARTIS AG·Filed 2021·Granted Jan 28, 2025·0 cites·26 claims
- 3770US11905283B2Compounds and compositions for inhibiting the activity of SHP2NOVARTIS AG·Filed 2020·Granted Feb 20, 2024·0 cites·8 claims
- 3869US8293769B2CSF-1R inhibitors, compositions, and methods of useNG SIMON C·Filed 2008·Granted Oct 23, 2012·2 cites·39 claims
- 3968US2014301976A1Novel hydroxamates as therapeutic agentsPHARMACYCLICS INC·Filed 2014·Application pending·0 cites
- 4066US10308660B2Compounds and compositions for inhibiting the activity of SHP2CHEN ZHUOLIANG·Filed 2016·Granted Jun 4, 2019·1 cites·20 claims
- 4165US2024216378A1Triazolopyrimidine compounds and uses thereofNOVARTIS AG·Filed 2024·Application pending·0 cites
- 4263US2025092036A1Compounds and compositions for modulating the activity of erkNOVARTIS AG·Filed 2024·Application pending·0 cites
- 4362US2007293540A1Novel hydroxamates as therapeutic agentsVERNER ERIK J·Filed 2007·Application pending·0 cites
- 4462US2025223277A1Complement factor b inhibitors and uses thereofNOVARTIS AG·Filed 2023·Application pending·0 cites
- 4562US2019142837A1Triazolopyrimidine compounds and uses thereofNOVARTIS AG·Filed 2019·Application pending·0 cites
- 4661US2025115572A1Spirocyclic piperidinyl derivatives as complement factor b inhibitors and uses thereofNOVARTIS AG·Filed 2023·Application pending·0 cites
- 4759US2014275083A13-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idhCAFERRO THOMAS RAYMOND·Filed 2014·Application pending·0 cites
- 4857US10112931B23-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDHNOVARTIS AG·Filed 2017·Granted Oct 30, 2018·0 cites·11 claims
- 4957US2024216513A1Fatty acid-bifunctional degrader conjugates and their methods of useNOVARTIS AG·Filed 2022·Application pending·0 cites
- 5057US2008139547A1Acetylene derivatives as inhibitors of histone deacetylasePHARMACYCLICS INC·Filed 2008·Application pending·0 cites
Showing the top 50 of 58 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →